Iguratimod

Overview of the drug Iguratimod

Iguratimod
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Iguratimod is a disease-modifying antirheumatic drug (DMARD) used primarily in the treatment of rheumatoid arthritis. It is known for its anti-inflammatory and immunomodulatory effects. Iguratimod is particularly noted for its ability to inhibit the production of inflammatory cytokines and the activation of NF-_B.

Mechanism of Action

Iguratimod works by modulating the immune response. It inhibits the production of pro-inflammatory cytokines such as TNF-_, IL-1, and IL-6. Additionally, it suppresses the activation of NF-_B, a transcription factor that plays a key role in the inflammatory response. This dual action helps reduce inflammation and slow the progression of joint damage in rheumatoid arthritis.

Pharmacokinetics

Iguratimod is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily in the urine. The drug has a half-life that allows for once-daily dosing, which can improve patient compliance.

Clinical Use

Iguratimod is used in the management of rheumatoid arthritis, particularly in patients who have not responded adequately to other DMARDs. It can be used as monotherapy or in combination with other antirheumatic drugs such as methotrexate.

Side Effects

Common side effects of iguratimod include gastrointestinal disturbances, such as nausea and diarrhea, as well as liver enzyme elevations. Patients on iguratimod require regular monitoring of liver function tests. Less commonly, it may cause leukopenia or thrombocytopenia.

Contraindications

Iguratimod is contraindicated in patients with known hypersensitivity to the drug. It should be used with caution in patients with liver impairment or a history of liver disease.

Related Pages

• Rheumatoid arthritis
• Disease-modifying antirheumatic drug
• Cytokine
• Nuclear factor kappa-light-chain-enhancer of activated B cells

• 

  Iguratimod